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To the editor: In a recent paper by Hauser et al. in this 
journal, a prevalence of 10.8% of transmitted drug-
resistant viruses was reported among newly diagnosed 
HIV cases in Germany in 2013 and 2014 [1]. The authors 
conclude that genotypic resistance testing remains 
important for treatment as well as HIV prevention. We 
comment on the use of pre-exposure prophylaxis (PrEP) 
in relation to drug resistance in HIV infections and the 
need for European surveillance of drug resistance.
PrEP with tenofovir and emtricitabine prevents new HIV 
infections in persons at high risk of acquiring HIV [2]. 
In 2016, the European Commission approved emtricit-
abine/tenofovir disoproxil once per day for PrEP. France 
and Norway are the only two countries in Europe fully 
reimbursing PrEP but many more are considering imple-
menting PrEP pilot projects in 2017 and 2018 [3]. PrEP 
is cost effective with the current drug prices [4,5] and 
a generic version of tenofovir and emtricitabine is 
expected in 2017 or 2018, which may reduce the costs 
and lead to more widespread use of PrEP in Europe.
PrEP use also poses some challenges as the included 
drugs are part of the recommended first and second 
line regimens to treat HIV-infected individuals. The 
resistance patterns that develop against either drug 
in a situation of therapy failure are well known: the 
primary mutation selected by tenofovir that causes a 
diminished treatment response is the K65R amino acid 
substitution in the reverse transcriptase. In addition, 
the presence of multiple thymidine-associated muta-
tions (TAMs) selected by zidovudine, a previously 
frequently used drug in HIV treatment, can affect the 
effect of tenofovir on the virus. In individuals failing 
emtricitabine (or the commonly used lamivudine)-
containing regimens, the amino acid changes M184I/V 
are frequently seen [6]. Viruses with these mutations 
can be transmitted, resulting in the failure of tenofovir/
emtricitabine-based PrEP [7,8].
The use of PrEP by individuals infected with HIV but 
unaware of this can lead to the generation of resist-
ant viruses in these individuals. Transmission to, or 
selection in, an HIV-positive person on PrEP carries the 
risk of forward transmission of these resistant virus to 
other individuals (both on and off PrEP).
Therefore, we recommend surveillance on national level 
as well European level. As mentioned by Hauser et al., 
Germany has a mandatory notification system of new 
HIV diagnoses, but this is not the case in all European 
countries [1]. In addition, baseline genotypic resist-
ance testing is not routinely performed in all countries. 
We recommend the surveillance network Strategy to 
Control Spread of HIV Drug Resistance (SPREAD) to col-
lect these data [9]. SPREAD is organised in 28 coun-
tries by the European Society of Antiviral Research 
(ESAR) and monitors drug-resistant viruses in newly 
diagnosed individuals [10]. SPREAD can add the use 
of PrEP in the baseline questionnaire and install a reg-
istry within the existing SPREAD database, collecting 
data on selection of resistant viruses and treatment 
and/or prophylaxis failure due to PrEP use. In this way, 
we hope that outbreaks of PrEP-resistant viruses will 
be identified in a timely manner.
In conclusion, as PrEP for HIV prevention is expected to 
be rolled out in European countries in the near future, 
and considering the informal use of PrEP in the commu-
nity, we suggest including variables on PrEP use in the 
European surveillance SPREAD programme, increasing 
the proportion of baseline resistance testing in newly 
diagnosed HIV infections and installing a registry on 
the selection of resistant viruses and failure of PrEP 
within the existing SPREAD database.
Note
Disclaimer: This paper is the view of the authors and not nec-
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